Navigation Links
diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
Date:9/29/2008

SOUTH SAN FRANCISCO, CALIF., Sept. 29 /PRNewswire/ -- diaDexus, Inc. today announced its partnership with the Living Heart Foundation (LHF), a non-profit organization dedicated to combating cardiovascular disease in current and retired NFL players. The PLAC(R) Test will be included as part of the LHF's cardiovascular risk assessment and disease prevention program designed to identify individuals at elevated risk for suffering a heart attack or stroke.

The PLAC Test is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease and ischemic stroke associated with atherosclerosis. The PLAC Test measures lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis that cause the majority of cardiac events. Clinical research demonstrates that early diagnosis of cardiovascular disease improves the likelihood of preventing these events.

"Traditional risk factors fail to identify many people at risk for developing cardiovascular disease," said Dr. Archie Roberts, founder of the Living Heart Foundation and a former NFL Quarterback. "We are pleased to offer the PLAC Test which provides new information, beyond traditional risk factors, to help identify those individuals with an increased chance of suffering from a cardiovascular event, allowing them to take the necessary steps to improve not only their health, but also their chance of survival."

Dr. Roberts created the LHF to encourage athletes to educate themselves on the importance of early detection and aggressive management of cardiovascular disease through free health clinics and events. The cardiovascular risk assessment and disease prevention programs held around the country will also contribute to research conducted by the LHF exploring the relationship between professional football players and cardiovascular disease.

"I'm thankful the LHF has incorporated the PLAC Test into their health program, as it was an eye opener for my overall health," said David O'Brien, former NFL player for the Minnesota Vikings, New York Giants and St. Louis Cardinals. "I never had heart problems, and my cholesterol was under control so I assumed I was not at risk for a heart attack or stroke. The PLAC Test identified my hidden risk for these events and enabled my doctors to prescribe an aggressive treatment program to lower my risk."

diaDexus is donating the PLAC Test kits for the LHF cardiovascular risk assessment and disease prevention program.

About diaDexus

diaDexus, Inc., a privately held diagnostics company based in South San Francisco, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. For more information, visit http://www.plactest.com or http://www.diaDexus.com.

About the Living Heart Foundation (LHF)

Living Heart Foundation (LHF) is a 501 (c) (3) entity with a national network of hospitals and physicians that unite to fight cardiovascular disease (CVD). The Foundation emphasizes CVD awareness, education, objective testing, early diagnosis and credible research. The 5-year-old ongoing NFL retired player screening/study has a database of over 1,400 former players.


'/>"/>
SOURCE diaDexus, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Touch Bionics acquires LIVINGSKIN
2. UCB Scholarship Program Awards $300,000 to Students Living with Crohns Disease
3. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
4. ATS Medical Expands Open Pivot Heart Valve Offerings
5. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
6. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
7. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
8. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
9. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
10. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
11. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... 2017 , ... Proscia Inc. , a data solutions ... whole slide imaging solutions, are hosting a pre-conference workshop at the Digital ... Best-in-Class Strategy for Digital Pathology,” will feature Proscia CEO, David West Jr., and ...
(Date:9/20/2017)... ... 2017 , ... RoviSys, a leading independent provider of comprehensive ... an office in Taipei, Taiwan. This new location allows RoviSys to better support ... in the region. Located in the Neihu area of Taipei, the office allows ...
(Date:9/19/2017)... , ... September 19, 2017 , ... VetStem Biopharma ’s CEO and founder, Dr. ... PhD in Riordan’s new book "Stem Cell Therapy: A Rising Tide". Dr. Harman and ... They bonded over an interest in the potential of stem cell therapy and a ...
(Date:9/19/2017)... ... September 19, 2017 , ... Avomeen Analytical Services, ... of its 2017 Science Student Award. The scholarship program is dedicated to helping ... service defray the costs of obtaining their science education. , Avomeen began the ...
Breaking Biology Technology:
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):